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a b s t r a c t
Triple-negative breast cancer (TNBC) accounts for !10–20% of breast cancers and is associated with rel-
atively poor prognosis, earlier disease recurrence and higher number of visceral metastases. Despite an
increasing understanding of the molecular heterogeneity of TNBC, clinical trials of targeted agents have
thus far been disappointing; chemotherapy, in particular with anthracycline and taxanes, remains the
backbone medical management for both early and metastatic TNBC. Nab-paclitaxel is a solvent-free,
albumin-bound, nanoparticle formulation of paclitaxel and represents a novel formulation of an estab-
lished, effective chemotherapeutic agent. Nab-paclitaxel has been specifically designed to overcome
the limitations of conventional taxane formulations, including the barriers to effective drug delivery of
highly lipophilic agents. It has shown significant efficacy and better tolerability than conventional tax-
anes in metastatic breast cancer and is approved for use in this setting. Increasing evidence suggests that
nab-paclitaxel is effective in patients with more aggressive tumours, as seen in TNBC. Indeed, results of
Phase II/III studies indicate that nab-paclitaxel may be effective as neoadjuvant treatment of TNBC. This
article reviews the rationale and evidence supporting a role for nab-paclitaxel in the treatment of TNBC,
including ongoing studies such as ADAPT-TN and tnAcity. In addition, the article reviews ongoing
research into targeted therapies and immuno-oncology for the treatment of TNBC, and explores the
potential role, current evidence and ongoing studies of nab-paclitaxel as the chemotherapy partner in
combination with immunotherapy, where the unique properties of this taxane, including the lack of
requirement for steroid pre-medication, may present an advantage.
! 2016 Published by Elsevier Ltd.
Background
Triple-negative breast cancer (TNBC), which is defined accord-
ing to a lack of oestrogen receptor (ER) and progesterone (PgR)
receptor expression, and human epidermal growth factor receptor
2 (HER2) overexpression, accounts for approximately 10–20% of
malignant breast tumours [1–3], and is encountered more fre-
quently in specific patient groups, such as younger women, those
of Afro-American origin, and those with BRCA mutations [3]. At
presentation, triple-negative (TN) tumours are typically larger in
size and of higher grade than other breast cancers; they are also
associated with an aggressive clinical behaviour, frequently result-
ing in early metastatic dissemination, particularly to visceral sites
[3]. As such, TNBC is associated with a relatively poor prognosis
compared with other subtypes [2]. Indeed, data from clinical
reports as well as real world data indicate that the median overall
survival (OS) for patients with metastatic TNBC is much shorter
than that for patients with other metastatic breast cancer (MBC)
subtypes (9–13.3 months vs. 28 months, respectively) [4–11].
Breast cancer tumours are classified into four main intrinsic
molecular subtypes according to their gene expression profiles:
luminal A, luminal B, HER2-enriched and basal-like [12]. TNBC
most closely associates with the basal-like subgroup, but the over-
lap is not absolute; approximately 72% of TN tumours are basal-
like, others share molecular characteristics with the luminal A
(5%), luminal B (6%) and HER2-enriched (9%) subtypes, and the
remaining 8% are normal-like tumours [13]. TN tumours also often
share a gene expression profile that is present in breast cancers
with BRCA1 dysfunction, a feature often referred to as ‘BRCAness’
[8,14]. In 2011, a seminal study by Lehmann and colleagues sought
to sub-classify TNBC using gene expression profiling; based on
their results, seven distinct molecular subtypes with differing
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biological features, driver mutations for cell growth, natural his-
tory and clinical behaviour were identified: basal-like 1 (BL1),
basal-like 2 (BL2), mesenchymal (M), mesenchymal stem-like
(MSL), immunomodulatory (IM), luminal androgen receptor (LAR)
and unclassified (U) [15]. These subtypes differ in terms of progno-
sis and in vitro response to targeted therapy [15,16]. More recently,
a simplified algorithm using small gene sets has been developed
that can recapitulate the TNBC subtypes identified by the original
2188-gene model of Lehmann et al. and reliably predict therapeu-
tic response to standard chemotherapy [17].
Clinical trials of targeted agents in TNBC have thus far been dis-
appointing. As such, the mainstay medical management for TNBC
remains chemotherapy [18,19]. Taxane/anthracycline-containing
regimens are the preferred option in the neoadjuvant and adjuvant
settings, with various other agents also listed as options by the
main international guidelines [18–21]. There is also increasing
support for the use of platinum-based regimens for TNBC based
on evidence from several randomized controlled trials [22–31],
making them an important treatment option for this patient pop-
ulation [18–21]. However, there is still an urgent need for more
effective treatments for patients with this breast cancer subtype.
Nab-paclitaxel is a next–generation taxane that has been specif-
ically designed to overcome the limitations of conventional taxane
formulations, including the barriers to effective drug delivery of
highly lipophilic agents [32]. In this article, we provide an overview
of the pharmacological properties and suggested mechanism of
action of nab-paclitaxel, and discuss how these features translate
into improved clinical efficacy and tolerability, as demonstrated
in MBC. In particular, we present the latest data on the use of
nab-paclitaxel in TNBC and summarize recently completed and
ongoing trials of therapeutic agents designed to target the molec-
ular aberrations of TNBC subtypes.
Nab-paclitaxel: a novel tumour-targeted therapy comprising an
old chemotherapy drug
Paclitaxel has been available for 25 years and its efficacy in the
treatment of breast cancer is well established. However, due to its
highly lipophilic nature and the need to formulate using a solvent
(Cremophor EL) and ethanol, its use is associated with a number of
challenges. These include increased risk of hypersensitivity
(requiring pre-treatment of patients with a corticosteroid/antihis-
tamine) and prolonged sensory neuropathy, non-linear pharma-
cokinetics and a toxicity profile that limits dose escalation. The
limitations of traditional taxanes (i.e. paclitaxel and docetaxel)
have been reviewed extensively in previous publications [33–36].
Nab-paclitaxel is a novel formulation of paclitaxel, consisting of
a colloidal suspension of albumin-bound paclitaxel nanoparticles
with a mean diameter of 130 nm [37]. The paclitaxel particles
are associated with albumin through non-covalent, hydrophobic
interactions, allowing for rapid dissociation of the paclitaxel
nanoparticles when administered intravenously [36]. Importantly,
nab-paclitaxel is not formulated using a solvent and, thus, is devoid
of solvent-associated hypersensitivity reactions, toxicities and dos-
ing complications; its use does not require pre-medication
[36,38,39]. Nab-paclitaxel is pharmacologically distinct from
solvent-based paclitaxel, having linear pharmacokinetics and a
higher maximum tolerated dose than paclitaxel [32,40–44]. In
addition, by exploiting the natural interactions between albumin
and the gp60/caveolin-1 receptor pathway, nab-paclitaxel is asso-
ciated with rapid and preferential delivery and accumulation of
paclitaxel at the tumour site [32,36,38,45]. Indeed, pharmacoki-
netic studies have shown that, compared with paclitaxel,
nab-paclitaxel is associated with a 9-fold greater penetration of
paclitaxel into tissues via transporter-mediated pathways, a 33%
higher intratumoural drug concentration, a 10-fold higher mean
maximal concentration of free paclitaxel, and a 4-fold lower
elimination rate [38,45,46].
The suggested mechanism of action of nab-paclitaxel is shown
in Fig. 1. Briefly, nab-paclitaxel binds to the albumin-specific recep-
tor glycoprotein, gp60, on the endothelial cell surface, which acti-
vates caveolin-1 leading to the creation of vesicles (caveolae) that
transcytose across the cell cytoplasm. The caveolae then fuse with
the cell membrane and release their contents into the tumour
interstitial space; there, the drug binds to albumin-binding pro-
teins, which may include SPARC (secreted protein acidic and rich
in cysteine), although data are inconsistent [47–53], with no corre-
lation between SPARC expression and clinical efficacy demon-
strated in recent Phase III clinical trials [54,55]. The accumulation
of nab-paclitaxel via albumin-binding proteins at the tumour cell
membranes allows for diffusion of paclitaxel into the intracellular
compartment and subsequent induction of tumour cell death [36].
Nab-paclitaxel for the management of TNBC: ongoing and
completed clinical trials
Nab-paclitaxel has demonstrated superior efficacy compared
with paclitaxel in Phase III trials in unselected breast cancer popu-
lations, both in the early [56] and metastatic setting [57]. In MBC,
findings from a systematic review have shown that nab-paclitaxel
is the only agent to demonstrate a survival benefit as second line
therapy in a clinical trial setting [58]. Moreover, exploratory anal-
yses conducted using data from Phase II [59] and III [57] trials sug-
gest that nab-paclitaxel is an effective treatment strategy in
patients with poor prognostic factors, such as a short disease-free
interval, a higher number of metastatic sites (P3) and predomi-
nantly visceral disease [60,61]. As TNBC is often characterized by
poor prognosis, visceral metastasis and early recurrence [3–7],
nab-paclitaxel may be considered as an option for these patients.
Indeed, exploration of the role of nab-paclitaxel in patients with
TNBC is an area of much interest and active research, with trials
undertaken in both the metastatic (Table 1) and neoadjuvant
(Table 2) settings. Many of these studies have exclusively recruited
patients with TNBC, although some have been conducted in a
broader population and included a subgroup analysis of those with
TNBC. Of note, nab-paclitaxel is dosed on a weekly basis for
3 weeks out of every four (QW 3/4) in most of the studies. The
rationale for this approach is based on the increased efficacy
observed with weekly paclitaxel, both for metastatic [62–64] and
early breast cancer [65,66]. Furthermore, findings from several
Phase II studies of nab-paclitaxel indicate significant efficacy in
MBC with weekly schedules of 100 mg/m2, 125 mg/m2, 130 mg/m2
and 150 mg/m2 in first and subsequent lines [59,67,68],
although concerns remain about the toxicity of weekly doses of
150 mg/m2 [69]. In the early breast cancer setting, data from the
Phase III GeparSepto study have shown that 12 continuous weekly
doses of nab-paclitaxel 125 mg/m2 given as the taxane component
of neoadjuvant therapy is both well tolerated and associated with
superior pathologic complete response (pCR) rates vs. weekly
paclitaxel 80 mg/m2 [56]. In this trial, the original nab-paclitaxel
dose was 150 mg/m2, but this was reduced to 125 mg/m2 in a
protocol amend after 464 patients had been treated following tox-
icity concerns with the higher dose. Another Phase III study (ETNA)
evaluated treatment with four cycles of nab-paclitaxel 125 mg/m2
QW 3/4 vs. paclitaxel 90 mg/m2 QW 3/4 as the taxane component
of neoadjuvant therapy [70]. This trial provided important infor-
mation regarding the required dose intensity for nab-paclitaxel
as neoadjuvant therapy, since it included a less dose-intense
nab-paclitaxel regimen compared with the GeparSepto trial [70].
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Results from ETNA were presented at the 2016 ASCO annual meet-
ing [71] and will be discussed later in this article.
It is notable that several studies evaluating nab-paclitaxel in
TNBC include a platinum agent in the treatment regimen. This is
likely because several randomized trials conducted in patients
with basal-like TN breast cancer have shown that cisplatin and car-
boplatin were associated with greater pCR rates (neoadjuvant set-
ting) and improved overall response rates (ORR) and/or slightly
longer OS (metastatic setting) compared with non-platinum-
based therapies [23,25–28,30,31]. This likely reflects the fact that
basal-like TN tumours are frequently associated with BRCA muta-
tions or homologous recombination deficiency (HRD) [72–74],
which appear to be more sensitive to platinum agents [28,75–78].
Of the eleven studies in the advanced/metastatic setting
(Table 1), four have been completed [79–82] and, of these, three
have reported results. One of these was a Phase II trial which eval-
uated the combination of nab-paclitaxel with gemcitabine and
bevacizumab as first-line treatment in metastatic HER2-negative
breast cancer [79]. In a subgroup analysis of patients with TNBC
in this trial (n = 13), the ORR was 69%, compared with 75.9% in
the overall population (n = 29). PFS and OS at 18 months were
10.6% and 82.5%, respectively; values that were not significantly
different from those in patients with hormone receptor-positive
disease. The authors described the clinical benefit rate (CBR;
ORR + stable disease [SD]) in the TNBC subgroup (84.6%) as excep-
tionally high [79]. In the second completed Phase II study, which
was comprised exclusively of patients with metastatic TNBC
(n = 34), first-line treatment with nab-paclitaxel, carboplatin and
bevacizumab was associated with an ORR of 85%, a CBR of 94%,
and a median PFS of 9.2 months [81]. The third was a Phase III ran-
domized controlled trial which compared first-line treatment with
bevacizumab 10 mg/kg on Days 1 and 15 Q4W combined with
either paclitaxel 90 mg/m2 (arm A), nab-paclitaxel 150 mg/m2
(arm B) or ixabepilone 16 mg/m2 (arm C), all QW 3/4, in 799
women with MBC [82]. Arm C was closed for futility at the first
interim analysis and arm A and arm B were also closed for futility
at the second interim analysis. Without considering ixabepilone
results, nab-paclitaxel was not superior to paclitaxel (PFS 9.3 vs.
11.0 months; hazard ratio (HR) 1.20; 95% confidence interval (CI)
1.00–1.45; p = 0.054). Similar results were seen in terms of OS. In
an unplanned, exploratory subset analysis of patients with TNBC,
there was also no significant difference in terms of PFS between
nab-paclitaxel and paclitaxel (median PFS 7.4 and 6.5 months,
respectively; HR 0.86; 95% CI 0.60–1.25; p = 0.43). Despite the pos-
sible confounder of the addition of bevacizumab, this is the only
Phase III trial comparing weekly nab-paclitaxel with weekly pacli-
taxel in the advanced setting that also provides data for the TN
subgroup. Although results from this trial confirmed good activity
with nab-paclitaxel, albeit without demonstrating superiority to
paclitaxel, this trial also showed that nab-paclitaxel 150 mg/m2
QW 3/4 in combination with bevacizumab was too toxic in
this patient population, as revealed by the higher rates of
GradeP3 toxicity, dose reductions and discontinuations in the
nab-paclitaxel/bevacizumab arm compared with the paclitaxel/
bevacizumab arm [82].
Amongst the ongoing studies, data are available from a Phase II
study which compared nab-paclitaxel monotherapy with
nab-paclitaxel plus the anti-death receptor 5 monoclonal antibody,
tigatuzumab, in 64 patients with TNBC (any line) [83]. Although
the combination was well tolerated, the addition of tigatuzumab
did not improve the ORR or PFS compared with nab-paclitaxel
alone. However, there was prolonged clinical benefit in four
patients treated first-line with the combination. Although it was
not the aim of the trial, the results support the activity of
nab-paclitaxel in advanced TNBC.
Other ongoing studies in the advanced setting have yet to report
data. The largest of these exclusively in patients with TNBC is
tnAcity (Triple-Negative Albumin-bound paclitaxel Combination
International Treatment Study), which is a Phase II/III trial evaluat-
ing nab-paclitaxel 125 mg/m2 QW for 2 weeks out of every three
(2/3) in combination with either gemcitabine or carboplatin vs.
gemcitabine plus carboplatin [84,85]. Recruitment to the 3-arm,
Phase II part of this trial is complete, and results will determine
which of the nab-paclitaxel doublet combinations will be com-
pared with gemcitabine plus carboplatin in the Phase III part of
the trial. Considering the results of the Phase III TNT (Triple
Negative Trial), which showed no difference in efficacy between
carboplatin and docetaxel for the first-line treatment of metastatic
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Fig. 1. Nab-paclitaxel delivery to tumour cells via albumin-binding proteins.
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TNBC in the overall study population, but superior efficacy for car-
boplatin in the subgroup of patients with germline BRCAmutations
[86], tnAcity will provide interesting information on the specific
efficacy of a first-line taxane-platinum regimen in the TN setting.
Another ongoing study that exclusively includes patients with
advanced TNBC is evaluating induction therapy with six courses
of weekly nab-paclitaxel plus bevacizumab, with responders
receiving bevacizumab or erlotinib until disease progression or
unacceptable toxicity [87]. The remaining ongoing studies are eval-
uating nab-paclitaxel in broader breast cancer populations. These
include a Phase II study of weekly nab-paclitaxel monotherapy in
patients P65 years with all types of breast cancer [88], the Phase
II SNAP study comparing three different nab-paclitaxel regimens
in HER2-negative disease [89], and the Phase I/II ABRAMYO study
evaluating the combination of nab-paclitaxel and liposomal dox-
orubicin, also in HER2-negative MBC [90].
Many of the trials evaluating nab-paclitaxel in the neoadjuvant
setting have reported data (Table 2). Four of these studies
[56,71,91,92] were conducted in a broader range of breast cancer
subtypes, with data also reported for the TNBC subgroup. In a
Phase II study conducted by Mrozek and colleagues, which evalu-
ated the combination of weekly nab-paclitaxel and carboplatin
plus bevacizumab in 33 patients with HER2-negative breast cancer,
pCR was achieved only in the subgroup of patients with TNBC
(n = 12), with a pCR rate in this subgroup of 50% (6/12) [91]. Sim-
ilarly, in a Phase II study of weekly nab-paclitaxel and carboplatin
plus panitumumab in 24 patients with inflammatory breast cancer,
a higher pCR rate was achieved in the TNBC subgroup of patients
(56% vs. 20% in the non-TNBC subgroup) [92]. Notably, in the large
Phase III GeparSepto study, pCR rates were significantly greater
with nab-paclitaxel compared with paclitaxel in the overall patient
population (38.4% vs. 29.0%; p = 0.001) and were doubled for those
with TNBC (48% vs. 26%; p < 0.001) [56]. Although long-term out-
comes data from GeparSepto are yet to be reported, these results
are encouraging given that patients who achieve a pCR seem to
achieve a survival benefit compared with those who do not
[4,93–95]. Indeed, in a pooled analysis of data from over 6000
patients treated with neoadjuvant anthracycline-taxane-based
chemotherapy in seven randomized trials, pCR was associated with
improved disease-free survival (DFS) in a number of breast cancer
subtypes, including TNBC, and the authors concluded that pCR is a
suitable surrogate endpoint for TNBC [95]. A more recent analysis
of data from nearly 12,000 women with breast cancer also showed
that the association between pCR and long-term outcomes was
particularly strong in those with aggressive tumour subtypes; in
TNBC, the HR (95% CI) for event-free survival (EFS) and OS were
0.24 (0.18–0.33) and 0.16 (0.11–0.25), respectively [94]. However,
there is insufficient data to validate pCR as surrogate endpoint for
survival.
The previously mentioned Phase III ETNA trial compared nab-
paclitaxel and paclitaxel in a taxane-anthracycline/cyclophospha
mide ± fluorouracil (T-AC/EC/FEC) neoadjuvant regimen in patients
with HER2-negative, high-risk breast cancer [70], with patients
stratified according to tumour subtype. The primary endpoint of
this trial was pCR, with secondary endpoints including a compar-
ison between pCR achieved in luminal vs. TN disease. Unlike
GeparSepto, results from the ETNA trial failed to show a statisti-
cally significant improvement in pCR rates with nab-paclitaxel
compared with paclitaxel in either the overall population (22.5%
vs. 18.1%, respectively; p = 0.127) or in the TNBC subgroup (41.3%
vs. 35.5%, respectively; p = 0.376), although numerical improve-
ments were apparent. Although it is difficult to compare results
from these two trials, one possible explanation for the lack of a sig-
nificant improvement in pCR in the ETNA trial is the lower dose
intensity of nab-paclitaxel used (125 mg/m2 QW 3/4 – equivalent
to 93.75 mg/m2/week, compared with 125 mg/m2/week inTa
bl
e
2
N
ab
-p
ac
lit
ax
el
st
ud
ie
s
in
th
e
ne
oa
dj
uv
an
t
se
tt
in
g.
A
ut
ho
rs
/t
ri
al
Ph
as
e
Tr
ia
l
po
pu
la
ti
on
Tr
ea
tm
en
ts
pC
R
ra
te
s
St
at
us
M
ro
ze
k
et
al
.[
91
]
II
H
ER
2"
(s
ub
gr
ou
p
an
al
ys
is
fo
r
TN
BC
)
#
N
ab
-P
10
0
m
g/
m
2
+
ca
rb
op
la
ti
n
A
U
C2
Q
W
3/
4
+
be
va
ci
zu
m
ab
10
m
g/
kg
D
1,
15
Q
4W
50
%
(p
CR
ac
hi
ev
ed
on
ly
in
TN
BC
)
Co
m
pl
et
ed
M
at
su
da
et
al
.[
92
]
II
In
fla
m
m
at
or
y
BC
(s
ub
gr
ou
p
an
al
ys
is
fo
r
TN
BC
)
#
N
ab
-P
10
0
m
g/
m
2
+
ca
rb
op
la
ti
n
A
U
C2
+
pa
ni
tu
m
um
ab
2.
5
m
g/
kg
Q
W
$
4
fo
llo
w
ed
by
5-
flu
or
ou
ra
ci
l5
00
m
g/
m
2
+
ep
ir
ub
ic
in
10
0
m
g/
m
2
+
cy
cl
op
ho
sp
ha
m
id
e
50
0
m
g/
m
2
Q
W
$
4
36
%
(6
0%
in
TN
BC
su
bg
ro
up
)
Co
m
pl
et
ed
G
ep
ar
Se
pt
o
(N
CT
01
58
34
26
)
[5
6,
13
1]
III
A
ll
ty
pe
s
of
BC
(s
ub
gr
ou
p
an
al
ys
is
fo
r
TN
BC
)
#
N
ab
-P
15
0
m
g/
m
2
w
ee
kl
y
fo
r
12
w
#
Pa
cl
it
ax
el
80
m
g/
m
2
w
ee
kl
y
fo
r
12
w
N
ab
-P
:
48
.2
%
O
ng
oi
ng
(p
ri
m
ar
y
en
dp
oi
nt
da
ta
pu
bl
is
he
d)
Bo
th
fo
llo
w
ed
by
ep
ir
ub
ic
in
90
m
g/
m
2
+
cy
cl
op
ho
sp
ha
m
id
e
60
0
m
g/
m
2
Q
3W
$
4
Pa
cl
it
ax
el
:
25
.7
%
(p
<
0.
00
1)
A
D
A
PT
-T
N
(N
CT
01
81
52
42
)
[9
6,
11
0]
II/
III
TN
BC
#
N
ab
-P
12
5
m
g/
m
2
+
ge
m
ci
ta
bi
ne
10
00
m
g/
m
2
D
1,
8
Q
3W
$
4
#
N
ab
-P
12
5
m
g/
m
2
+
ca
rb
op
la
ti
n
A
U
C2
D
1,
8
Q
3W
$
4
O
ve
ra
ll:
36
%
O
ng
oi
ng
N
ab
-P
+
ge
m
ci
ta
bi
ne
:
25
%
N
ab
-P
+
ca
rb
op
la
ti
n:
49
.2
%
(p
=
0.
00
6)
ET
N
A (N
CT
01
82
23
14
)
[7
0]
[7
1]
III
H
ER
2"
(s
ub
gr
ou
p
an
al
ys
is
fo
r
TN
BC
)
#
N
ab
-P
12
5
m
g/
m
2
Q
W
3/
4
$
4
#
Pa
cl
it
ax
el
90
m
g/
m
2
Q
W
3/
4
$
4
O
ve
ra
ll:
N
ab
-P
22
.5
%,
Pa
c
18
.1
%;
p
=
0.
12
7
(T
N
BC
:
N
ab
-P
:
41
.3
%,
35
.5
%;
p
=
0.
37
6)
O
ng
oi
ng
(p
ri
m
ar
y
en
dp
oi
nt
da
ta
pr
es
en
te
d)
Bo
th
fo
llo
w
ed
by
st
an
da
rd
EC
,A
C
or
FE
C
Q
3W
$
4
N
CT
01
52
59
66
[9
8]
II
TN
BC
#
Ca
rb
op
la
ti
n
D
1
Q
4W
+
na
b-
P
w
ee
kl
y
$
4
–
Re
cr
ui
ti
ng
Sa
ch
de
v
et
al
.[
97
]
II
TN
BC
#
N
ab
-P
10
0
m
g/
m
2
Q
W
3/
4
+
ca
rb
op
la
ti
n
A
U
C6
Q
3W
$
4
fo
llo
w
ed
by
do
xo
ru
bi
ci
n
60
m
g/
m
2
+
cy
cl
op
ho
sp
ha
m
id
e
60
0
m
g/
m
2
Q
3W
$
4
Br
ea
st
:
56
%
Cl
os
ed
du
e
to
sl
ow
ac
cr
ua
l
Be
va
ci
zu
m
ab
10
m
g/
kg
D
1,
15
Q
4W
du
ri
ng
fir
st
si
x
cy
cl
es
of
pr
eo
pe
ra
ti
ve
CT
an
d
po
st
-o
pe
ra
ti
ve
ly
to
co
m
pl
et
e
1
ye
ar
of
tr
ea
tm
en
t
Br
ea
st
an
d
no
de
s:
53
%
A
C,
do
xo
ru
bi
ci
n
+
cy
cl
op
ho
sp
ha
m
id
e;
BC
,b
re
as
t
ca
nc
er
;
CT
,c
he
m
ot
he
ra
py
;
EC
,e
pi
ru
bi
ci
n
+
cy
cl
op
ho
sp
ha
m
id
e;
FE
C,
5-
flu
or
ou
ra
ci
l+
ep
ir
ub
ic
in
+
cy
cl
op
ho
sp
ha
m
id
e;
na
b-
P,
na
b-
pa
cl
it
ax
el
;
pC
R,
co
m
pl
et
e
pa
th
ol
og
ic
al
re
sp
on
se
;
TN
BC
,t
ri
pl
e-
ne
ga
ti
ve
br
ea
st
ca
nc
er
.
F. Schettini et al. / Cancer Treatment Reviews 50 (2016) 129–141 133
GeparSepto). Although the dose intensity of paclitaxel was also
lower in ETNA (90 mg/m2 QW 3/4 – equivalent to 67.5 mg/m2/
week, compared with 80 mg/m2/week in GeparSepto), the relative
reduction in dose intensity between the two trials was greater for
nab-paclitaxel (25% reduction in dose intensity with nab-paclitaxel
compared with a 16% reduction in dose intensity with paclitaxel)
[71].
Amongst the trials evaluating nab-paclitaxel in the neoadjuvant
setting exclusively in patients with TNBC, data from the ADAPT-TN
Phase II trial, which compared 12 weeks of nab-paclitaxel
125 mg/m2 QW 2/3 plus either gemcitabine 1000 mg/m2 or
carboplatin area under the curve (AUC) 2 in 336 patients with
TNBC, have recently been reported [96]. Findings from this trial
showed that the combination of nab-paclitaxel plus carboplatin
is associated with a greater pCR than nab-paclitaxel plus
gemcitabine (ypT0/is, ypN0: 45.2% vs. 25.8%; ypT0, ypN0:
45.9% vs. 28.7%; p < 0.001). In another Phase II trial, which
evaluated the combination of weekly nab-paclitaxel plus
carboplatin followed by doxorubicin plus cyclophosphamide with
concurrent bevacizumab in 42 patients with TNBC, interim data
for the first 30 evaluable patients showed an in-breast pCR rate
of 56% and a breast plus node pCR rate of 53% [97]. Unfortunately,
this trial was closed early due to slow accrual.
An additional trial of weekly nab-paclitaxel in the neoadjuvant
setting is currently ongoing. This is a single-arm Phase II study
evaluating the combination of nab-paclitaxel and carboplatin in
TNBC, with a primary endpoint of pCR or Symmans criteria of
0–1 and an estimated completion date of January 2017 [98].
Apart from data from randomized clinical trials, several case
reports for the use of nab-paclitaxel in patients with TNBC have
been published. Although anecdotal, these reports also indicate
that treatment with nab-paclitaxel, either alone or as part of
combination therapy, is feasible and effective with strong and
prolonged responses and acceptable toxicity reported [99–102].
Taken together, these data demonstrate that nab-paclitaxel is a
potent and effective taxane for the management of breast cancer,
with impressive efficacy also reported in patients with TNBC.
Ongoing trials, particularly tnAcity, will provide further evidence
to help define the role of nab-paclitaxel in TNBC in the future.
Future perspectives
As clinical trials of targeted agents in TNBC have thus far been
disappointing, it is likely that chemotherapy will remain the back-
bone of TNBC treatment in the near future. For patients with early
stage TNBC, greater benefit may be derived from intensive neoad-
juvant chemotherapy regimens, since attainment of pCR has been
associated with a better prognosis [4,94,95,103]. In this context,
data from GeparSepto provide compelling evidence for the prefer-
ential use of nab-paclitaxel as the taxane component of a 12-week
T-AC neoadjuvant regimen in patients with TNBC [56]. However,
long-term data are still awaited to see if this improvement in
pCR translates into an EFS or OS benefit. Lack of regulatory
approval also limits the current use of nab-paclitaxel in this setting.
For patients with metastatic TNBC, exploratory data from a
randomized, Phase III study in MBC indicate that three-weekly
nab-paclitaxel is effective in achieving a rapid tumour response
in patients with features of aggressive disease [60,104]. As weekly
conventional paclitaxel is more effective than a three-weekly reg-
imen, it is conceivable that a weekly approach could also improve
outcomes with nab-paclitaxel, and there is growing support for its
use in selected patients [69]. Indeed, weekly nab-paclitaxel is
included as an option for MBC in NCCN (but not EU) treatment
guidelines [21]; however, the weekly schedule of nab-paclitaxel
is not currently licensed for use in MBC. Results of the tnAcity trial
of weekly nab-paclitaxel-containing regimens will therefore
provide more robust evidence to clarify the optimal use of
nab-paclitaxel in metastatic TNBC.
Although nab-paclitaxel appears to be a highly effective
chemotherapy for the management of TNBC, further work is
needed to improve outcomes for this patient population. Indeed,
an increased understanding of the molecular heterogeneity of
TNBC may pave the way for more successful therapy in the future.
The gene expression profiles of different TNBC subtypes and corre-
sponding therapies that may prove useful in these subtypes are
summarized in Table 3. Currently, there are several ongoing Phase
II and III trials of these therapies in TNBC in the neo/adjuvant and
metastatic settings (Table 4), with some evaluating targeted agents
in combination with a taxane (including nab-paclitaxel) and/or a
platinum agent. However, most of these trials have not selected
patients according to genetically-defined TNBC subtypes, and it
will be interesting to see how these agents fare in overall TNBC
populations. In addition to these trials, it is also worth highlighting
that there are two ongoing trials of personalized genomic-based
therapy, one (the PETREMAC study) in high-risk breast cancer
[105] and one in TNBC [106].
Another key area of ongoing research in TNBC is the therapeutic
role of platinum agents. High pCR rates were observed when car-
boplatin was added to paclitaxel/doxorubicin in patients with
TNBC in the recent GeparSixto trial (53.2% with carboplatin vs.
36.9% without carboplatin, p = 0.005) [28], with early data for
long-term outcomes indicating that this improvement in pCR asso-
ciated with the addition of carboplatin also translates into a benefit
in DFS (HR 0.56; p = 0.0350) [31]. However, in the CALGB 40603
trial, which also demonstrated an improvement in pCR with the
addition of carboplatin to paclitaxel plus dose-dense (dd) AC in
patients with TNBC [29], attainment of a pCR was associated with
improved OS irrespective of treatment received (HR 0.20;
p < 0.001) and there was no treatment effect for the addition of car-
boplatin on EFS (HR 0.84; p = 0.36) [30]. In the metastatic setting,
the role of platinum agents in an unselected TNBC population, at
least as monotherapy, is currently uncertain given the results from
the TNT trial, which showed no difference in efficacy between car-
boplatin and docetaxel for the first-line treatment of metastatic
TNBC in the overall study population, but superior efficacy for car-
boplatin in the subgroup of patients with germline BRCAmutations
[86]. Given the current evidence base, international guidelines only
recommend the routine use of platinum agents for TNBC if patients
have known BRCAmutations [18–21]. However, several studies are
ongoing to further clarify the role of these agents in TNBC. A small
number of these studies are evaluating platinum monotherapy,
Table 3
Potential therapeutic approaches for TNBC subtypes according to gene expression
profiles [15,132].
TNBC
subtype
Gene expression profile Therapeutic targets
BL1 DNA damage response and cell
proliferation
PARP inhibitors
BL2 TP63, EGFR and MET signalling mTOR, growth factor inhibitors
IM Immune signalling PARP inhibitors
M EMT, Wnt, TGFb, IG1FR, notch,
cell proliferation
mTOR, growth factor inhibitors
Src inhibitors
MSL EMT, Wnt, TGFb, MAPK, Rac,
PI3K, PDGF
mTOR, PI3K, MEK and growth
factor inhibitors
LAR AR signalling, FOXA1 and ERBB4
signalling
AR antagonists, PI3K inhibitors
UNC DNA damage response and cell
proliferation
PARP inhibitors
AR, androgen receptor; BL, basal-like; EGFR, epidermal growth factor receptor; IM,
immunomodulatory; LAR, luminal androgen receptor, M, mesenchymal; MSL,
mesenchymal stem-like, UNC, unclassified.
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Table 4
Key ongoing trials of novel immunotherapy and targeted agents in TNBC.
Agent Phase Setting/trial population Regimen(s) Line Status Trial
identifier
Immune checkpoint inhibitors
Nivolumab
[128,129]
I Metastatic TNBC included in one of three arms of
the trial (total n = 138)
# Nivolumab + nab-paclitaxel I or II Recruiting NCT02309177
Atezolizumab
[117,118]
IB Metastatic TNBC (n = 32) included in one of six arms
of the trial (total n = 225)
# Atezolizumab + nab-paclitaxel I-III Recruiting NCT01633970
Atezolizumab
[120]
III Metastatic TNBC (n = 900) # Atezolizumab + nab-paclitaxel
# Placebo + nab-paclitaxel
I Recruiting NCT02425891
Atezolizumab
[124]
II Early TNBC (n = 37) # Atezolizumab + nab-paclitaxel (4 cycles)
thenatezolizumab (4 cycles) post-surgery
Neoadjuvant
& adjuvant
Recruiting NCT02530489
Atezolizumab
[119]
III Early TNBC (n = 272) # Atezolizumab + nab-paclitaxel +
carboplatin then AC/EC or FEC
post-surgery
# Nab-paclitaxel + carboplatin then
AC/EC or FEC post-surgery
Neoadjuvant Not yet
recruiting
NCT02620280
Pembrolizumab
[121]
III Previously untreated locally recurrent or inoperable
metastatic TNBC (n = 858)
# Pembrolizumab + nab-paclitaxel
# Pembrolizumab + paclitaxel
# Pembrolizumab + carboplatin
+ gemcitabine
# Placebo + nab-paclitaxel
# Placebo + paclitaxel
# Placebo + carboplatin + gemcitabine
I Recruiting NCT02819518
Pembrolizumab
[127]
II 2 cohorts: Metastatic TNBC (n = 30) and HER2- MBC
(n = 20)
# Pembrolizumab + nab-paclitaxel I-III Recruiting NCT02752685
Pembrolizumab
[126]
I Early TNBC (n = 80) # Pembrolizumab + nab-paclitaxel then
AC
# Pembrolizumab + nab-paclitaxel +
carboplatin then AC
Neoadjuvant Recruiting NCT02622074
Durvalumab
[125]
I/II Early TNBC (n = 61) # Durvalumab + nab-paclitaxel then
durvalumab + ddAC
Neoadjuvant Recruiting NCT02489448
Durvalumab
[123]
II Early TNBC (n = 174) # Durvalumab + nab-paclitaxel then
durvalumab + EC
# Placebo + nab-paclitaxel thenplacebo + EC
Neoadjuvant Not yet
recruiting
NCT02685059
PARP inhibitors
Veliparib (ABT-
888) [133]
III Early TNBC (n = 624) # Veliparib + carboplatin + paclitaxel
then AC
# Placebo + carboplatin + paclitaxel then
AC
# Placebo + placebo + paclitaxel then AC
Neoadjuvant Recruiting NCT02032277
Veliparib (ABT-
888) [134]
II Metastatic TNBC or BRCA mutation-associated
(n = 235)
# Cisplatin + veliparib
# Cisplatin + placebo
I or II Not yet
recruiting
NCT02595905
Olaparib [135] III Germline BRCA mutated, high risk, HER2 negative
primary breast cancer (n = 1500)
# Olaparib
# Placebo
Adjuvant Recruiting NCT02032823
Talazoparib
[136]
II Advanced TNBC or HER2- BC with mutation in
homologous recombination pathway genes (n = 58)
# Talazoparib II+ Recruiting NCT02401347
Rucaparib [137] II TNBC with BRCA1/2 mutations (n = 135) # Rucaparib + cisplatin
# Cisplatin
Adjuvanta Ongoing NCT01074970
mTOR inhibitors
Everolimus
[138]
II TNBC (n = 62) # Paclitaxel + everolimus then FEC
# Paclitaxel then FEC
Neoadjuvant Ongoing NCT00499603
PI3K inhibitors
BKM120 [139] II Metastatic TNBC (n = 50) # BKM120 6III Ongoing NCT01629615
Ipatasertib
(GDC-0068)
[140]
II Early TNBC (n = 150) # Paclitaxel + ipatasertib
# Paclitaxel + placebo
Neoadjuvant Recruiting NCT02301988
Ipatasertib
(GDC-0068)
[141]
II Inoperable locally advanced or metastatic TNBC
(n = 120)
# Paclitaxel + ipatasertib
# Paclitaxel + placebo
I Recruiting NCT02162719
MEK inhibitors
Cobimetinib
[142]
II Metastatic TNBC (n = 112) # Paclitaxel + cobimetinib
# Paclitaxel + placebo
I Recruiting NCT02322814
AR antagonists
Bicalutamide
[143]
II AR + metastatic TNBC (n = 60) # Bicalutamide
# Physician’s choice of treatment
II + I Not yet
started
NCT02353988
(continued on next page)
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either in single-arm studies [107] or vs. other chemotherapies
[108] or observation [109]. However, most studies are assessing
platinum agents in combination with other chemotherapies,
including nab-paclitaxel (see Tables 1 and 2). The combination of
nab-paclitaxel plus carboplatin has been associated with a high
ORR in a small Phase II trial in metastatic TNBC [81] and a signifi-
cant improvement in pCR compared with nab-paclitaxel plus gem-
citabine in the ADAPT-TN trial [96]. Further information regarding
the efficacy of nab-paclitaxel plus a platinum agent will be derived
from the tnAcity trial [84,85] as well as long-term outcomes data
from the ADAPT-TN trial [96,110].
An increasingly important area of current and future research in
TNBC is the use of immunotherapy. Indeed, TNBC has a high muta-
tional load which may confer higher immunogenicity compared
with other subtypes [111]. Thus, TNBC may respond well to new-
generation immunotherapeutic drugs, such as agents that target
cytotoxic T-lymphocyte-associated protein 4 (CTLA4) or pro-
grammed death ligand 1 (PD-L1) or its receptor, PD-1. Their use
in combination with chemotherapies is of particular interest, as
cytotoxic agents may help to reinstate anti-tumour immunity via
a number of mechanisms, including [112]:
# tumour debulking, which reduces the systemic immunosup-
pressive activity of malignant cells,
# increased expression or presentation of tumour-associated anti-
gens on the surface of cancer cells,
# stimulation and expression of death receptors on tumour cells
which, in the presence of their ligands, induce apoptotic or
necrotic cell death and promote the secretion of multiple
cytokines and chemokines, including CXCL1, CCL2, interleukin
(IL)-6, and IL-8,
# alteration of the surface proteome of cancer cells, making them
more susceptible to the cytotoxic activity of various innate and
adaptive immune effectors.
Although different chemotherapeutic agents each elicit a dis-
crete effect on the tumour and host immune system, no systematic
analysis has been conducted to identify the optimal chemothera-
peutic agent to use with immunotherapeutic drugs in order to
maximize potential synergistic effects. However, there is emerging
evidence to suggest that paclitaxel may be a rational combination
partner, as it has been shown to induce secretion of
pro-inflammatory cytokines from macrophages, leading to den-
dritic cell, natural killer cell and T-cell activation; to promote anti-
gen presentation by bone marrow dendritic cells to T cells; and to
augment Th1 cellular immunity by increasing the levels of circulat-
ing interferon (IFN)-c-secreting CD8 T-cells and IL-2-secreting CD4
T-cells [113]. However, as nab-paclitaxel does not require steroid
premedication, which may dampen the immune system and lead
to steroid-induced protection of tumour cells against immunother-
apy [114], this agent may be preferred over conventional pacli-
taxel. Indeed, findings from preclinical studies indicate that
treatment with nab-paclitaxel plus the anti-PD-L1, atezolizumab,
shows synergistic antitumour activity [115].
Against this background, there are a number of ongoing trials
evaluating the combination of nab-paclitaxel with immune check-
point inhibitors in breast cancer (Table 4). Amongst these, a multi-
centre, Phase Ib study has recently reported data showing
promising activity with the combination of nab-paclitaxel plus ate-
zolizumab in 24 patients with metastatic TNBC; the confirmed ORR
(defined as P2 consecutive assessments of complete or partial
response according to Response Evaluation Criteria in Solid
Tumours [RECIST] v1.1 [116]) in all patients was 38% and was
higher in patients receiving the combination as first-line (46%,
n = 13) vs. second-line (22%, n = 9) or Pthird-line (40%, n = 10)
therapy (Fig. 2 for impact of treatment on tumour burden over
time according to line of therapy) [117,118]. Ongoing Phase III tri-
als are NeoTRIPaPDL1 [119], IMpassion130 [120] and KEYNOTE-
355 [121], all of which are evaluating nab-paclitaxel plus either
atezolizumab or pembrolizumab in TNBC. NeoTRIPaPDL1 is evalu-
ating neoadjuvant therapy with nab-paclitaxel plus carbo-
platin ± atezolizumab in locally advanced TNBC [119], whereas
IMpassion130 is evaluating nab-paclitaxel ± atezolizumab in previ-
ously untreated metastatic TNBC and KEYNOTE-355 is evaluating
chemotherapy (nab-paclitaxel, paclitaxel or carboplatin + gemc-
itabine) ± pembrolizumab in previously untreated metastatic TNBC
[120–122]. In the early breast cancer setting, four other studies of
nab-paclitaxel with immune checkpoint inhibitors are ongoing.
The first is being conducted by the German Breast Group (GBG)
and is a randomized Phase II trial (GeparNuevo) to evaluate
the addition of durvalumab to a neoadjuvant regimen of
nab-paclitaxel followed by epirubicin plus cyclophosphamide in
Table 4 (continued)
Agent Phase Setting/trial population Regimen(s) Line Status Trial
identifier
Enzalutamide
[144]
II AR + advanced TNBC (n = 118) # Enzalutamide ND Ongoing NCT01889238
EGF inhibitors
ABX [145] II Advanced TNBC (n = 254) # ABX + cisplatin
# Gemcitabine + cisplatin
I Not yet
started
NCT02546934
Nimotuzumab
[146]
II Recurrent/metastatic TNBC (n = 90) # Nimotuzumab + docetaxel
+ capecitabine
# Docetaxel + capecitabine
Ib Recruiting NCT01939054
VEGF inhibitors
Bevacizumab
[147]
II Advanced TNBC (n = 304) # Carboplatin + cyclophosphamide
+ bevacizumab
# Carboplatin + cyclophosphamide
# Paclitaxel + bevacizumab
# Paclitaxel
Ic Recruiting NCT01898117
AC, anthracycline/cyclophosphamide; AR, androgen receptor; BC, breast cancer; ddAC, dose-dense anthracycline/cyclophosphamide; EC, epirubicin/cyclophosphamide; EGF,
epidermal growth factor; FEC, fluorouracil/epirubicin/cyclophosphamide; MBC, metastatic breast cancer; ND, not defined; TNBC, triple-negative breast cancer; VEGF, vascular
endothelial growth factor.
Note: This is not an exhaustive list of clinical trials of targeted agents for TNBC; trials were selected for inclusion in the table based on their size, design (inclusion of control
arm) and/or population (genetic mutations).
a Patients must have completed pre-operative (neoadjuvant) therapy and definitive resection of the primary tumour, but not adjuvant therapy
b Previous chemotherapy should include anthracycline or taxane; however, patients must have received no prior chemotherapy after metastasis
c Patients must have received no previous cytotoxic therapy for metastatic disease.
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TNBC [123]. The other three are smaller trials; one Phase II trial of
nab-paclitaxel plus atezolizumab as neoadjuvant therapy followed
by surgery and adjuvant atezolizumab therapy in 37 patients with
TNBC [124], a Phase I/II trial of nab-paclitaxel plus durvalumab fol-
lowed by ddAC plus durvalumab as neoadjuvant therapy in 61
patients with TNBC [125], and KEYNOTE-173, a Phase I trial of
nab-paclitaxel ± carboplatin plus pembrolizumab followed by AC
as neoadjuvant therapy in 80 patients with TNBC [126]. In the
metastatic setting, an additional two studies are underway. One
is a Phase II trial evaluating nab-paclitaxel plus pembrolizumab
in two separate cohorts: metastatic TNBC (n = 30) and HER2- MBC
(n = 20) [127], and the other is a Phase I three-arm trial that is
evaluating the addition of nivolumab to nab-paclitaxel in 138
patients with either metastatic pancreatic cancer (±gemcitabine),
non-small cell lung cancer (with carboplatin) or TNBC [128,129].
The results of these trials are awaited with interest, although fur-
ther biomarker research is required to help predict which patients
might benefit more from this therapeutic approach.
Concluding remarks
Given the aggressive nature of TNBC, fast-acting and effective
chemotherapy is likely to remain the backbone of therapy for many
patients. Nab-paclitaxel is a next-generation taxane with a superior
therapeutic index to paclitaxel, as demonstrated in Phase III trials
[56,57]. It may be a particularly attractive treatment choice in
TNBC since it has a better tolerability profile which permits higher
dosing, and it is thought to utilize active transport mechanisms to
facilitate rapid drug delivery. Indeed, clinical data reported to-date
support the preferential selection of nab-paclitaxel in TNBC: in the
neoadjuvant setting, nab-paclitaxel was associated with a doubling
in pCR rate (48.2% vs. 25.7%) in GeparSepto [56] and a similarly
high pCR rate (49.2%) when combined with carboplatin in the
ADAPT-TN trial [96], and there are data from Phase II trials to sup-
port its efficacy in metastatic TNBC [79,81], although these data
require confirmation from larger, randomized trials such as
tnAcity.
There appears to be a strong scientific rationale and impressive
early clinical data for nab-paclitaxel in combination with new
immunotherapies, such as immune checkpoint inhibitors, suggest-
ing that it may represent a valuable chemotherapy combination
partner. As such, there is growing enthusiasm for this approach,
and results from ongoing trials are awaited with interest. Indeed,
it is hoped that results from these trials as well as those evaluating
novel agents according to therapeutic targets identified in specific
subgroups of TNBC, may help to redefine treatment algorithms in
this difficult-to-treat breast cancer subtype, and herald a new era
of personalized treatment.
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Fig. 2. Changes in tumour burden over time following treatment with nab-
paclitaxel plus atezolizumab (PD-L1 checkpoint inhibitor) in patients with
metastatic TNBC (a) as first-line therapy, (b) as second-line therapy, and (c) as
third-line or greatera therapy. Reproduced with permission from ‘Phase Ib trial of
atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-
negative breast cancer (mTNBC)’ by Adams et al., poster presentation at the 2016
ASCO annual meeting [118]. aOne patient received three prior lines of therapy PD-
L1 IC0 defined as <1% IC expressing PD-L1 as a percentage of tumour area. PD-L1
IC1/2/3 defined asP1% IC expressing PD-L1 as a percentage of tumour area. ASCO,
American Society of Clinical Oncology; CR, complete response; IC, immune cells;
mTNBC, metastatic triple negative breast cancer; PD-L1, programmed death ligand
1; PR, partial response.
F. Schettini et al. / Cancer Treatment Reviews 50 (2016) 129–141 137
Acknowledgements
The authors received medical writing support in the prepara-
tion of this manuscript from Angela Corstorphine of Kstorfin Med-
ical Communications Ltd. This support was funded by Celgene
International Sàrl. The authors take full responsibility for all con-
tent and editorial decisions for this manuscript.
References
[1] Brewster AM, Chavez-MacGregor M, Brown P. Epidemiology, biology, and
treatment of triple-negative breast cancer in women of African ancestry.
Lancet Oncol 2014;15:e625–34.
[2] Boyle P. Triple-negative breast cancer: epidemiological considerations and
recommendations. Ann Oncol 2012;23(Suppl. 6):vi7–vi12.
[3] Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, et al.
Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol
2012;30:1879–87.
[4] Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to
neoadjuvant therapy and long-term survival in patients with triple-negative
breast cancer. J Clin Oncol 2008;26:1275–81.
[5] Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant
recurrence and clinical outcomes in patients with metastatic triple-negative
breast cancer: high incidence of central nervous system metastases. Cancer
2008;113:2638–45.
[6] Kassam F, Enright K, Dent R, Dranitsaris G, Myers J, Flynn C, et al. Survival
outcomes for patients with metastatic triple-negative breast cancer:
implications for clinical practice and trial design. Clin Breast Cancer
2009;9:29–33.
[7] Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-
negative breast cancer: clinical features and patterns of recurrence. Clin
Cancer Res 2007;13:4429–34.
[8] Bayraktar S, Gluck S. Molecularly targeted therapies for metastatic triple-
negative breast cancer. Breast Cancer Res Treat 2013;138:21–35.
[9] Bonotto M, Gerratana L, Poletto E, Driol P, Giangreco M, Russo S, et al.
Measures of outcome in metastatic breast cancer: insights from a real-world
scenario. Oncologist 2014;19:608–15.
[10] Braiteh F, Parisi M, Ni Q, Park SY, Faria C. Comparative effectiveness of early-
line nab-paclitaxel vs paclitaxel in patients with hormone receptor-positive/
HER2-negative or triple-negative metastatic breast cancer: a US community-
based real-world analysis. In: 33rd annual Miami breast cancer conference,
Miami Beach, FL, USA; 2016. p. 372.
[11] Braiteh F, Parisi M, Ni Q, Park SY, Faria C. Comparative effectiveness of early-
line nab-paclitaxel vs eribulin in patients with hormone receptor–positive/
HER2-negative or triple-negative metastatic breast cancer: a community-
based real-world analysis. In: NCCN 21st annual conference, Hollywood, FL,
USA; 2016.
[12] Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al.
Molecular portraits of human breast tumours. Nature 2000;406:747–52.
[13] Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer.
Mol Oncol 2011;5:5–23.
[14] Oonk AM, van Rijn C, Smits MM, Mulder L, Laddach N, Savola SP, et al. Clinical
correlates of ‘BRCAness’ in triple-negative breast cancer of patients receiving
adjuvant chemotherapy. Ann Oncol 2012;23:2301–5.
[15] Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al.
Identification of human triple-negative breast cancer subtypes and
preclinical models for selection of targeted therapies. J Clin Invest
2011;121:2750–67.
[16] Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, et al.
Molecular profiling of the residual disease of triple-negative breast cancers
after neoadjuvant chemotherapy identifies actionable therapeutic targets.
Cancer Discovery 2014;4:232–45.
[17] Ring BZ, Hout DR, Morris SW, Lawrence K, Schweitzer BL, Bailey DB, et al.
Generation of an algorithm based on minimal gene sets to clinically subtype
triple negative breast cancer patients. BMC Cancer 2016;16:143.
[18] Cardoso F, Costa A, Norton L, Senkus E, Aapro M, Andre F, et al. ESO-ESMO 2nd
international consensus guidelines for advanced breast cancer (ABC2). Ann
Oncol 2014;25:1871–88.
[19] Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al.
Primary breast cancer: ESMO clinical practice guidelines for diagnosis,
treatment and follow-up. Ann Oncol 2015;26(Suppl. 5):v8–v30.
[20] Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M,
et al. Tailoring therapies-improving the management of early breast cancer:
St Gallen international expert consensus on the primary therapy of early
breast cancer 2015. Ann Oncol 2015;26:1533–46.
[21] NCCN. Clinical practice guidelines in oncology: breast cancer version 3.2015
Available from: http://www.nccn.org/professionals/physician_gls/pdf/breast.
pdf2015 [accessed 16 February 2016].
[22] Bhattacharyya GS, Basu S, Agarwal V. Single institution phase II study of
weekly cisplatinum and metronomic dosing of cyclophosphamide and
methotrexate in second line metastatic breast cancer triple negative. Eur J
Cancer 2009;18(Suppl. 7). abstract 41.
[23] Alba E, Chacon JI, Lluch A, Anton A, Estevez L, Cirauqui B, et al. A randomized
phase II trial of platinum salts in basal-like breast cancer patients in the
neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study.
Breast Cancer Res Treat 2012;136:487–93.
[24] Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, et al. TBCRC 001:
randomized phase II study of cetuximab in combination with carboplatin in
stage IV triple-negative breast cancer. J Clin Oncol 2012;30:2615–23.
[25] Fan Y, Xu BH, Yuan P, Ma F, Wang JY, Ding XY, et al. Docetaxel-cisplatin might
be superior to docetaxel-capecitabine in the first-line treatment of metastatic
triple-negative breast cancer. Ann Oncol 2013;24:1219–25.
[26] Zhang P, Yin Y, Xu B, Wang X, Zhang B, Li Q, et al. Carboplatin plus paclitaxel
compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for
triple-negative breast cancer: a phase II clinical trial. In: Presented at the San
Antonio Breast Cancer Symposium, San Antonio, TX, USA; 2013. p. P3-14-07.
[27] Ando M, Yamauchi H, Aogi K, Shimizu S, Iwata H, Masuda N, et al.
Randomized phase II study of weekly paclitaxel with and without
carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as
neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2
overexpression. Breast Cancer Res Treat 2014;145:401–9.
[28] von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al.
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive
early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet
Oncol 2014;15:747–56.
[29] Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al.
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant
once-per-week paclitaxel followed by dose-dense doxorubicin and
cyclophosphamide on pathologic complete response rates in stage II to III
triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol
2015;33:13–21.
[30] SikovW,BerryD, PerouC, SinghB, CirrincioneC, TolaneyS, et al. Abstract S2-05:
event-free and overall survival following neoadjuvant weekly paclitaxel and
dose-dense AC +/" carboplatin and/or bevacizumab in triple-negative breast
cancer: outcomes from CALGB 40603 (Alliance). Cancer Res 2016;76:S2–5.
[31] von Minckwitz G, Loibl S, Schneeweiss A, Salat C, Rezai M, Zahm D-M, et al.
Abstract S2-04: early survival analysis of the randomized phase II trial
investigating the addition of carboplatin to neoadjuvant therapy for triple-
negative and HER2-positive early breast cancer (GeparSixto). Cancer Res
2016;76:S2–4.
[32] Li Y, Chen N, Palmisano M, Zhou S. Pharmacologic sensitivity of paclitaxel to
its delivery vehicles drives distinct clinical outcomes of paclitaxel
formulations. Mol Pharm 2015;12:1308–17.
[33] Schwartzberg LS. Taxanes: a cornerstone of treatment for metastatic breast
cancer. Commun Oncol 2008;5(Suppl. 8):3–6.
[34] ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of
formulation vehicles: implications for cancer chemotherapy. Clin
Pharmacokinet 2003;42:665–85.
[35] Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, et al. Failure of
higher-dose paclitaxel to improve outcome in patients with metastatic breast
cancer: cancer and leukemia group B trial 9342. J Clin Oncol 2004;22:2061–8.
[36] von Minckwitz G, Martin M, Wilson G, Alba E, Schmidt M, Biganzoli L, et al.
Optimizing taxane use in MBC in the emerging era of targeted chemotherapy.
Crit Rev Oncol Hematol 2013;85:315–31.
[37] Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and
nanoparticles. J Controlled Release 2008;132:171–83.
[38] Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased antitumor
activity, intratumor paclitaxel concentrations, and endothelial cell transport
of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with
cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317–24.
[39] EMA. Abraxane summary of product characteristicsAvailable from:
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_
Information/human/000778/WC500020435.pdf2008 [accessed 16 February
2016].
[40] Foote M. Using nanotechnology to improve the characteristics of
antineoplastic drugs: improved characteristics of nab-paclitaxel compared
with solvent-based paclitaxel. Biotechnol Annu Rev 2007;13:345–57.
[41] Viudez A, Ramirez N, Hernandez-Garcia I, Carvalho FL, Vera R, Hidalgo M.
Nab-paclitaxel: a flattering facelift. Crit Rev Oncol Hematol 2014;92:166–80.
[42] Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, et al.
Comparative preclinical and clinical pharmacokinetics of a cremophor-free,
nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated
in Cremophor (Taxol). Clin Cancer Res 2005;11:4136–43.
[43] Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, Trieu V, et al. Phase I
and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of
paclitaxel in patients with advanced nonhematologic malignancies. J Clin
Oncol 2005;23:7785–93.
[44] Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, et al.
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-
stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res
2002;8:1038–44.
[45] Chen N, Li Y, Ye Y, Palmisano M, Chopra R, Zhou S. Pharmacokinetics and
pharmacodynamics of nab-paclitaxel in patients with solid tumors:
disposition kinetics and pharmacology distinct from solvent-based
paclitaxel. J Clin Pharmacol 2014;54:1097–107.
[46] Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, et al.
Randomized crossover pharmacokinetic study of solvent-based paclitaxel
and nab-paclitaxel. Clin Cancer Res 2008;14:4200–5.
138 F. Schettini et al. / Cancer Treatment Reviews 50 (2016) 129–141
[47] Bertino EM, Williams TM, Nana-Sinkam SP, Shilo K, Chatterjee M, Mo X, et al.
Stromal caveolin-1 is associated with response and survival in a phase II trial
of nab-paclitaxel with carboplatin for advanced NSCLC patients. Clin Lung
Cancer 2015;16:466–74.
[48] Schneeweiss A, Seitz J, Smetanay K, Schuetz F, Jaeger D, Bachinger A, et al.
Efficacy of nab-paclitaxel does not seem to be associated with SPARC
expression in metastatic breast cancer. Anticancer Res 2014;34:6609–15.
[49] Neesse A, Frese KK, Chan DS, Bapiro TE, Howat WJ, Richards FM, et al. SPARC
independent drug delivery and antitumour effects of nab-paclitaxel in
genetically engineered mice. Gut 2014;63:974–83.
[50] Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, et al.
Gemcitabine plus nab-paclitaxel is an active regimen in patients with
advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011;29:4548–54.
[51] Lindner JL, Loibl S, Denkert C, Ataseven B, Fasching PA, Pfitzner BM, et al.
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast
cancer and response to neoadjuvant chemotherapy. Ann Oncol
2015;26:95–100.
[52] Blackwell K, Hamilton E, Rocha G, Gainey M, Trieu V, Motamed K, et al. SPARC
microenvironment signature (SMS) in patients treated with nab-paclitaxel
(nabP)/carboplatin (C)/bevacizumab(B) for triple-negative metastatic breast
cancer (TNMBC). J Clin Oncol 2010;28(Suppl. 15):e21040.
[53] Desai N, Trieu V, Damascelli B, Soon-Shiong P. SPARC expression correlates
with tumor response to albumin-bound paclitaxel in head and neck cancer
patients. Trans Oncol 2009;2:59–64.
[54] Hersh EM, Del Vecchio M, Brown MP, Kefford R, Loquai C, Testori A, et al. A
randomized, controlled phase III trial of nab-paclitaxel versus dacarbazine
in chemotherapy-naive patients with metastatic melanoma. Ann Oncol
2015;26:2267–74.
[55] Hidalgo M, Plaza C, Musteanu M, Illei P, Brachmann CB, Heise C, et al. SPARC
expression did not predict efficacy of nab-paclitaxel plus gemcitabine or
gemcitabine alone for metastatic pancreatic cancer in an exploratory analysis
of the phase III MPACT trial. Clin Cancer Res 2015;21:4811–8.
[56] Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C, et al. Nab-
paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for
early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet
Oncol 2016;17:345–56.
[57] Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III
trial of nanoparticle albumin-bound paclitaxel compared with polyethylated
castor oil-based paclitaxel in women with breast cancer. J Clin Oncol
2005;23:7794–803.
[58] Puglisi F, Rea D, Kroes MA, Pronzato P. Second-line single-agent
chemotherapy in human epidermal growth factor receptor 2-negative
metastatic breast cancer: a systematic review. Cancer Treat Rev 2016;43:
36–49.
[59] Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson
A, et al. Significantly longer progression-free survival with nab-paclitaxel
compared with docetaxel as first-line therapy for metastatic breast cancer. J
Clin Oncol 2009;27:3611–9.
[60] Ciruelos E, Jackisch C. Evaluating the role of nab-paclitaxel (Abraxane) in
women with aggressive metastatic breast cancer. Expert Rev Anticancer Ther
2014;14:511–21.
[61] O’Shaughnessy J, Gradishar WJ, Bhar P, Iglesias J. Nab-paclitaxel for first-line
treatment of patients with metastatic breast cancer and poor prognostic
factors: a retrospective analysis. Breast Cancer Res Treat 2013;138:829–37.
[62] Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, et al.
Randomized phase III trial of weekly compared with every-3-weeks
paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2
overexpressors and random assignment to trastuzumab or not in HER-2
nonoverexpressors: final results of cancer and leukemia group B protocol
9840. J Clin Oncol 2008;26:1642–9.
[63] Fountzilas G, Dafni U, Dimopoulos MA, Koutras A, Skarlos D, Papakostas P,
et al. A randomized phase III study comparing three anthracycline-free
taxane-based regimens, as first line chemotherapy, in metastatic breast
cancer: a hellenic cooperative oncology group study. Breast Cancer Res Treat
2009;115:87–99.
[64] Verrill MW, Lee J, Cameron DA, Agrawal R, Coleman RE, McAdam K, et al.
Anglo-celtic IV: first results of a UK national cancer research network
randomised phase 3 pharmacogenetic trial of weekly versus 3 weekly
paclitaxel in patients with locally advanced or metastatic breast cancer (ABC).
J Clin Oncol 2007;25. Abstract LBA1005.
[65] Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, et al.
Weekly paclitaxel improves pathologic complete remission in operable
breast cancer when compared with paclitaxel once every 3 weeks. J Clin
Oncol 2005;23:5983–92.
[66] Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, et al. Weekly
paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med
2008;358:1663–71.
[67] Blum JL, Savin MA, Edelman G, Pippen JE, Robert NJ, Geister BV, et al. Phase II
study of weekly albumin-bound paclitaxel for patients with metastatic breast
cancer heavily pretreated with taxanes. Clin Breast Cancer 2007;7:850–6.
[68] Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson
A, et al. Phase II trial of nab-paclitaxel compared with docetaxel as first-line
chemotherapy in patients with metastatic breast cancer: final analysis of
overall survival. Clin Breast Cancer 2012;12:313–21.
[69] Arpino G, Marme F, Cortes J, Ricevuto E, Leonard R, Llombart-Cussac A.
Tailoring the dosing schedule of nab-paclitaxel in metastatic breast cancer
according to patient and disease characteristics: recommendations from a
panel of experts. Crit Rev Oncol Hematol 2016;99:81–90.
[70] NCT01822314. Neoadjuvant chemotherapy with nab-paclitaxel in women
with HER2-negative high-risk breast cancer (ETNA). <https://clinicaltrials.
gov/ct2/show/NCT01822314> [accessed 6 March 2015].
[71] Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B, et al. ETNA
(evaluating treatment with neoadjuvant abraxane) randomized phase III
study comparing neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P)
both followed by anthracycline regimens in women with HER2-negative
high-risk breast cancer: a MICHELANGO study. J Clin Oncol 2016;34(Suppl).
abstract 502.
[72] Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, et al.
Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.
J Natl Cancer Inst 2003;95:1482–5.
[73] Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers.
Nat Rev Cancer 2004;4:814–9.
[74] Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, et al.
Incidence and outcome of BRCA mutations in unselected patients with triple
receptor-negative breast cancer. Clin Cancer Res 2011;17:1082–9.
[75] Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, et al.
BRCA1 functions as a differential modulator of chemotherapy-induced
apoptosis. Cancer Res 2003;63:6221–8.
[76] Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML, et al.
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937
human breast cancer cells. Br J Cancer 2003;88:1285–91.
[77] Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G, et al. Platinum-
based chemotherapy in triple-negative breast cancer. Ann Oncol
2008;19:1847–52.
[78] Telli M, McMillan A, Ford J, Richardson A, Silver D, Isakoff S, et al. Abstract P3-
07-12: homologous recombination deficiency (HRD) as a predictive
biomarker of response to neoadjuvant platinum-based therapy in patients
with triple negative breast cancer (TNBC): a pooled analysis. Cancer Res
2016;76. P3-07-12.
[79] Lobo C, Lopes G, Baez O, Castrellon A, Ferrell A, Higgins C, et al. Final results of
a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line
therapy for patients with HER2-negative metastatic breast cancer. Breast
Cancer Res Treat 2010;123:427–35.
[80] NCT00472693. Bevacizumab and abraxane as second-line therapy in triple
negative metastatic breast cancer. <https://www.clinicaltrials.gov/ct2/show/
NCT00472693?term=NCT00472693&rank=1> [accessed 21 February 2016].
[81] Hamilton E, Kimmick G, Hopkins J, Marcom PK, Rocha G, Welch R, et al. Nab-
paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple
negative metastatic breast cancer. Clin Breast Cancer 2013;13:416–20.
[82] Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Leung E, et al.
Randomized phase III trial of paclitaxel once per week compared with
nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone
with bevacizumab as first-line chemotherapy for locally recurrent or
metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin
Oncol 2015;33:2361–9.
[83] Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, et al.
TBCRC 019: a phase II trial of nanoparticle albumin-bound paclitaxel with
or without the anti-death receptor 5 monoclonal antibody tigatuzumab in
patients with triple-negative breast cancer. Clin Cancer Res 2015;21:
2722–9.
[84] Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Gluck S, et al. Phase II/
III weekly nab-paclitaxel plus gemcitabine or carboplatin versus
gemcitabine/carboplatin as first-line treatment of patients with metastatic
triple-negative breast cancer (the tnAcity study): study protocol for a
randomized controlled trial. Trials 2015;16:575.
[85] NCT01881230. Evaluate risk/benefit of nab paclitaxel in combination with
gemcitabine or carboplatin compared to gemcitabine and carboplatin in
triple negative metastatic breast cancer (tnAcity). <http://clinicaltrials.gov/
show/NCT01881230> [accessed 6 August 2015].
[86] Tutt A, Ellis P, Kilburn L, Gilett C, Pinder S, Abraham J, et al. Abstract S3-01:
the TNT trial: a randomized phase III trial of carboplatin (C) compared with
docetaxel (D) for patients with metastatic or recurrent locally advanced
triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Res 2015;75.
S3-01.
[87] NCT00733408. Paclitaxel albumin-stabilized nanoparticle formulation and
bevacizumab followed by bevacizumab and erlotinib hydrochloride in
treating patients with metastatic breast cancer. <https://www.clinicaltrials.
gov/ct2/results?term=NCT00733408&Search=Search> [accessed 21 February
2016].
[88] NCT01463072. Paclitaxel albumin-stabilized nanoparticle formulation in
treating older patients with locally advanced or metastatic breast cancer.
<https://www.clinicaltrials.gov/ct2/show/NCT01463072?term=NCT01463072&
rank=1> [accessed 21 February 2016].
[89] NCT01746225. Schedules of nab-paclitaxel inmetastatic breast cancer (SNAP).
<http://clinicaltrials.gov/ct2/show/NCT01746225?term=NCT01746225&
rank=1> [accessed 23 October 2014].
[90] Register ECT. Phase I-II study of weekly nab (nanoparticle albumin-bound)-
paclitaxel (nab-paclitaxel) in combination with liposomal encapsulated
doxorubicin (LDox) in patients with HER2 negative metastatic breast cancer
(ABRAMYO STUDY). EudraCT number 2013-005134-38. <https://
www.clinicaltrialsregister.eu/ctr-search/trial/2013-005134-38/IT> [accessed
21 February 2016].
F. Schettini et al. / Cancer Treatment Reviews 50 (2016) 129–141 139
[91] Mrózek E, Layman R, Ramaswamy B, Lustberg M, Vecchione A, Knopp MV,
et al. Phase II trial of neoadjuvant weekly nanoparticle albumin-bound
paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with
clinical stage II or III HER2-negative breast cancer. Clin Breast Cancer
2014;14:228–34.
[92] Matsuda N, Alvarez RH, Krishnamurthy S, Willey JS, Wang X, Lim B, et al.
Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by
FEC neoadjuvant chemotherapy for patients with primary HER-2 negative
inflammatory breast cancer. J Clin Oncol 2015;33(Suppl). abstract 1065.
[93] Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for
women with operable breast cancer. Cochrane Database Syst Rev 2007:
Cd005002.
[94] Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al.
Pathological complete response and long-term clinical benefit in breast
cancer: the CTNeoBC pooled analysis. Lancet 2014;384:164–72.
[95] von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA,
et al. Definition and impact of pathologic complete response on prognosis
after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J
Clin Oncol 2012;30:1796–804.
[96] Gluz O, Nitz U, Liedtke C, Christgen M, Sotlar K, Grischke E, et al. Abstract P1-
13-01: Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with
carboplatinum vs. gemcitabine in triple- negative breast cancer: WSG-ADAPT
TN randomized phase II trial. Cancer Res 2016;76. P1-13-01.
[97] Sachdev JC, Sinder J, Schwartzberg L, Young R, Yunus F, Allen J, et al. Interim
results of weekly nanoparticle albumin bound (nab)-paclitaxel plus
carboplatin followed by doxorubicin plus cyclophosphamide with
concurrent bevacizumab for triple-negative breast cancer. In: Presented at
the National Comprehensive Cancer Network Annual Conference; 2013:
Abstract AB2013-2.
[98] NCT01525966. Carboplatin and paclitaxel albumin-stabilized nanoparticle
formulation before surgery in treating patients with locally advanced or
inflammatory triple negative breast cancer. <https://www.clinicaltrials.gov/
ct2/show/NCT01525966?term=NCT01525966&rank=1> [accessed 21
February 2016].
[99] Arpino G, De Placido S, De Angelis C. Nab-paclitaxel for the management of
triple-negative metastatic breast cancer: a case study. Anticancer Drugs
2015;26:117–22.
[100] Shakir AR. Strong and sustained response to treatment with carboplatin plus
nab-paclitaxel in a patient with metastatic, triple-negative, BRCA1-positive
breast cancer. Case Rep Oncol 2014;7:252–9.
[101] Hara Y, Sakurai K, Enomoto K, Matsumoto K, Ueda Y, Hagiwara M, et al.
Complete response of advanced breast cancer with lymph node metastases to
nab-paclitaxel therapy-report of a case. Gan To Kagaku Ryoho 2012;39:
2080–2.
[102] Montero A, Glück S. Long-term complete remission with nab-paclitaxel,
bevacizumab, and gemcitabine combination therapy in a patient with triple-
negative metastatic breast cancer. Case Rep Oncol 2012;5:687–92.
[103] Berruti A, Amoroso V, Gallo F, Bertaglia V, Simoncini E, Pedersini R, et al.
Pathologic complete response as a potential surrogate for the clinical
outcome in patients with breast cancer after neoadjuvant therapy: a meta-
regression of 29 randomized prospective studies. J Clin Oncol 2014;32:
3883–91.
[104] O’Shaughnessy J, Gradishar WJ, Bhar P, Iglesias J. Nab-paclitaxel for first-line
treatment of patients with metastatic breast cancer and poor prognostic
factors: a retrospective analysis. Cancer Res 2012;72. P1-12-07.
[105] NCT02624973. PErsonalized TREatment of High-risk MAmmary cancer – the
PETREMAC trial (PETREMAC). <https://www.clinicaltrials.gov/ct2/show/
NCT02624973?term=NCT02624973&rank=1> [accessed 16 February 2016].
[106] NCT02101385. Randomized controlled trial of genomically directed therapy
in patients with triple negative breast cancer. <https://
www.clinicaltrials.gov/ct2/show/NCT02101385?term=NCT02101385&rank=
1> [accessed 16 February 2016].
[107] NCT00483223. Platinum for triple-negative metastatic breast cancer and
evaluation of p63/p73 as a biomarker of response. <https://
www.clinicaltrials.gov/ct2/show/NCT00483223?term=NCT00483223&rank=
1> [accessed 16 February 2016].
[108] NCT01982448. Cisplatin vs paclitaxel for triple Neg. <https://
www.clinicaltrials.gov/ct2/show/NCT01982448?term=NCT01982448&rank=
1> [accessed 16 February 2016].
[109] NCT02445391. Platinum based chemotherapy or observation in treating
patients with residual triple-negative basal-like breast cancer following
neoadjuvant chemotherapy. <https://www.clinicaltrials.gov/ct2/show/
NCT02445391?term=NCT02445391&rank=1> [accessed 16 February 2016].
[110] NCT01815242. Adjuvant dynamic marker-adjusted personalized therapy trial
optimizing risk assessment and therapy response prediction in early breast
cancer – triple negative breast cancer (ADAPT-TN), <https://clinicaltrials.gov/
ct2/show/NCT01815242> [accessed 6 March 2015].
[111] Criscitiello C, Curigliano G. Immunotherapy of breast cancer. Prog Tumor Res
2015;42:30–43.
[112] Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of
conventional and targeted anticancer therapies: reinstating immuno-
surveillance. Immunity 2013;39:74–88.
[113] Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of
cytotoxic chemotherapy: implications for the design of novel and rationale-
based combined treatments against cancer. Cell Death Differ 2014;21:15–25.
[114] Gruver-Yates AL, Cidlowski JA. Tissue-specific actions of glucocorticoids on
apoptosis: a double-edged sword. Cells 2013;2:202–23.
[115] Adams S, Diamond J, Hamilton E, Pohlmann P, Tolaney S, Molinero L, et al.
Abstract P2-11-06: safety and clinical activity of atezolizumab (anti-PDL1) in
combination with nab-paclitaxel in patients with metastatic triple-negative
breast cancer. Cancer Res 2016;76. P2-11-06.
[116] Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al.
New response evaluation criteria in solid tumours: revised RECIST guideline
(version 1.1). Eur J Cancer 2009;45:228–47.
[117] NCT01633970. A study of MPDL3280A administered in combination with
bevacizumab and/or with chemotherapy in participants with locally
advanced or metastatic solid tumors. <https://www.clinicaltrials.gov/ct2/
show/NCT01633970?term=NCT01633970&rank=1> [accessed 16 February
2016].
[118] Adams S, Diamond J, Hamilton E, Pohlmann P, Tolaney S, Molinero L, et al.
Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients
with metastatic triple-negative breast cancer (mTNBC). J Clin Oncol 2016;34
(Suppl). abstract 1009.
[119] NCT02620280. Neoadjuvant therapy in TRIPle negative breast cancer with
antiPDL1 (NeoTRIPaPDL1). <https://www.clinicaltrials.gov/ct2/show/
NCT02620280?term=NCT02620280&rank=1> [accessed 16 February 2016].
[120] NCT02425891. A study of atezolizumab (MPDL3280A) in combination with
nab-paclitaxel compared with placebo with nab-paclitaxel for patients with
previously untreatedmetastatic triple negative breast cancer (IMpassion130).
<https://clinicaltrials.gov/ct2/show/NCT02425891> [accessed 18 November
2015].
[121] NCT02819518. Study of pembrolizumab (MK-3475) Plus chemotherapy vs.
placebo plus chemotherapy for previously untreated locally recurrent
inoperable or metastatic triple negative breast cancer (MK-3475-355/
KEYNOTE-355). <https://clinicaltrials.gov/ct2/show/NCT02819518?term=
NCT02819518&rank=1> [accessed 5 August 2016].
[122] Emens L, Adams S, Loi S, Schmid P, Schneeweiss A, Rugo H, et al. Abstract
OT1-01-06: a phase III randomized trial of atezolizumab in combination with
nab-paclitaxel as first line therapy for patients with metastatic triple-
negative breast cancer (mTNBC). Cancer Res 2016;76. OT1-01-6.
[123] NCT02685059. Addition of PD-L1 antibody MEDI4736 to a taxane-
anthracycline chemotherapy in triple negative breast cancer (GeparNuevo).
<https://www.clinicaltrials.gov/ct2/show/NCT02685059?term=
GeparNuevo&rank=1> [accessed 16 February 2016].
[124] NCT02530489. Triple-negative first-line study: neoadjuvant trial of nab-
paclitaxel and MPDL3280A, a Pdl-1 inhibitor in patients with triple negative
breast cancer. <https://www.clinicaltrials.gov/ct2/show/NCT02530489?
term=NCT02530489&rank=1> [accessed 16 February 2016].
[125] NCT02489448. Neoadjuvant MEDI4736 concomitant with weekly
nab-paclitaxel and dose-dense AC for stage I–III triple negative breast
cancer. <https://www.clinicaltrials.gov/ct2/show/NCT02489448?term=
NCT02489448&rank=1> [accessed 16 February 2016].
[126] NCT02622074. Safety and efficacy study of pembrolizumab (MK-3475) in
combination with chemotherapy as neoadjuvant treatment for participants
with triple negative breast cancer (TNBC) (MK-3475-173/KEYNOTE 173).
<https://clinicaltrials.gov/ct2/show/NCT02622074?term=NCT02622074&
rank=1> [accessed 5 August 2016].
[127] NCT02752685. Phase II study of pembrolizumab and nab-paclitaxel in HER-2
negative metastatic breast cancer. <https://clinicaltrials.gov/ct2/show/
NCT02752685?term=NCT02752685&rank=1> [accessed 5 August 2016].
[128] NCT02309177. Safety study of nivolumab with nab-paclitaxel plus or minus
gemcitabine in pancreatic cancer, nab-paclitaxel/carboplatin in stage IIIB/IV
non-small cell lung cancer or nab-paclitaxel in recurrent metastatic breast
cancer. <https://clinicaltrials.gov/ct2/show/NCT02309177> [accessed 18
November 2015].
[129] Waterhouse D, Gutierrez M, Bekaii-Saab T, DeRosa W, Wainberg Z, George B,
et al. Abstract OT1-01-07: nab-paclitaxel (nab-P) plus nivolumab (Nivo) in
human epidermal growth factor receptor 2 (HER2)–negative recurrent
metastatic breast cancer (MBC). Cancer Res 2016;76. OT1-01-7.
[130] NCT01207102. Study of Abraxane" and carboplatin as first-line treatment for
triple negative metastatic breast cancer. <https://www.clinicaltrials.gov/ct2/
show/NCT01207102?term=NCT01207102&rank=1> [accessed 16 February
2016].
[131] NCT01583426. Study comparing nanoparticle-based paclitaxel with
solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients
with early breast cancer (GeparSepto). <http://clinicaltrials.gov/ct2/show/
NCT01583426?term=NCT01583426&rank=1> [accessed 23 October 2014].
[132] Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA. Subtyping of triple-
negative breast cancer: implications for therapy. Cancer 2015;121:8–16.
[133] NCT02032277. A study evaluating safety and efficacy of the addition of ABT-
888 plus carboplatin versus the addition of carboplatin to standard
chemotherapy versus standard chemotherapy in subjects with early stage
triple negative breast cancer. <https://www.clinicaltrials.gov/ct2/show/
NCT02032277?term=NCT02032277&rank=1> [accessed 21 February 2016].
[134] NCT02595905. Cisplatin with or without veliparib in treating patients
with stage IV triple-negative and/or BRCA mutation-associated breast
cancer. <https://www.clinicaltrials.gov/ct2/show/NCT02595905?term=
NCT02595905&rank=1> [accessed 16 February 2016].
[135] NCT02032823. Olaparib as adjuvant treatment in patients with germline
BRCA mutated high risk HER2 negative primary breast cancer (OlympiA).
140 F. Schettini et al. / Cancer Treatment Reviews 50 (2016) 129–141
<https://www.clinicaltrials.gov/ct2/show/NCT02032823> [accessed 21
February 2016].
[136] NCT02401347. Talazoparib beyond BRCA (TBB) trial, <https://
www.clinicaltrials.gov/ct2/show/NCT02401347?term=NCT02401347&rank=
1> [accessed 16 February 2016].
[137] NCT01074970. PARP inhibition for triple negative breast cancer (ER-/PR-/
HER2-) with BRCA1/2 mutations. <https://clinicaltrials.gov/ct2/show/
NCT01074970?term=NCT01074970&rank=1> [accessed 16 February 2016].
[138] NCT00499603. Paclitaxel followed by FEC versus paclitaxel and RAD001
followed by FEC in women with breast cancer. <https://clinicaltrials.gov/ct2/
show/NCT00499603?term=NCT00499603&rank=1> [accessed 16 February
2016].
[139] NCT01629615. A trial of BKM120 (a PI3K inhibitor) in patients with triple
negative metastatic breast cancer. <https://clinicaltrials.gov/ct2/show/
NCT01629615?term=NCT01629615&rank=1> [accessed 16 February 2016].
[140] NCT02301988. A study of ipatasertib (GDC-0068) in combination with
paclitaxel as neoadjuvant treatment for patients with early stage triple
negative breast cancer. <https://clinicaltrials.gov/ct2/show/NCT02301988?
term=NCT02301988&rank=1> [accessed 16 February 2016].
[141] NCT02162719. A study of ipatasertib (GDC-0068) in combination with
paclitaxel as front-line treatment for patients with metastatic triple-negative
breast cancer. <https://clinicaltrials.gov/ct2/show/NCT02162719?term=
NCT02162719&rank=1> [accessed 16 February 2016].
[142] NCT02322814. A study of cobimetinib in combination with paclitaxel as first-
line treatment for patients with metastatic triple-negative breast cancer.
<https://clinicaltrials.gov/ct2/show/NCT02322814?term=NCT02322814&
rank=1> [accessed 16 February 2016].
[143] NCT02353988.AR-inhibitorbicalutamide in treatingpatientswithTNBC(Arbre).
<https://clinicaltrials.gov/ct2/show/NCT02353988?term=NCT02353988&rank=
1> [accessed 16 February 2016].
[144] NCT01889238. Safety and efficacy study of enzalutamide in patients with
advanced, androgen receptor-positive, triple negative breast cancer.
<https://clinicaltrials.gov/ct2/show/NCT01889238?term=NCT01889238&
rank=1> [accessed 16 February 2016].
[145] NCT02546934. ABX plus cisplatin versus gemcitabine plus cisplatin in triple
negative breast cancer (TNBC). <https://clinicaltrials.gov/ct2/show/
NCT02546934?term=NCT02546934&rank=1> [accessed 16 February 2016].
[146] NCT01939054. Nimotuzumab plus docetaxel and capecitabine versus
docetaxel and capecitabine in the treatment of breast cancer patients.
<https://clinicaltrials.gov/ct2/show/NCT01939054?term=NCT01939054&
rank=1> [accessed 16 February 2016].
[147] NCT01898117. Triple-B study; carboplatin-cyclophosphamide versus
paclitaxel with or without bevacizumab as first-line treatment in advanced
triple negative breast cancer (Triple-B). <https://clinicaltrials.gov/ct2/show/
NCT01898117?term=NCT01898117&rank=1> [accessed 16 February 2016].
F. Schettini et al. / Cancer Treatment Reviews 50 (2016) 129–141 141
